Provided by Tiger Trade Technology Pte. Ltd.

JUNSHI BIO

19.400
+0.3601.89%
Volume:5.93M
Turnover:115.46M
Market Cap:19.92B
PE:-22.30
High:20.100
Open:19.580
Low:18.780
Close:19.040
52wk High:38.640
52wk Low:15.250
Shares:1.03B
HK Float Shares:260.00M
Volume Ratio:1.25
T/O Rate:2.28%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.870
ROE:-13.49%
ROA:-3.70%
PB:2.90
PE(LYR):-22.30
PS:6.27

Loading ...

AH Premium Rankings for August 27: A Market Overview

Stock News
·
7 hours ago

Shanghai Junshi Biosciences Estimates 35 Million Yuan in Related-Party Transactions

MT Newswires Live
·
8 hours ago

Press Release: Junshi Biosciences Announces 2026 Interim Financial Results and Provides Corporate Updates

Dow Jones
·
12 hours ago

Junshi Biosciences Reports First-Half Net Profit of RMB21.66 Million, Reversing Year-Earlier Loss

Stock News
·
23 hours ago

Junshi Bio Terminates 2026 A-Share Employee Stock Ownership Scheme

Bulletin Express
·
Yesterday

Shanghai Junshi Biosciences Return to Profit in H1

MT Newswires Live
·
Yesterday

Junshi Bio Turns Profitable as H1 2026 Revenue Leaps 45% to RMB1.70 Billion on Strong TUOYI® Momentum

Bulletin Express
·
Yesterday

Junshi Biosciences Swings to Profit in First-Half Results

Stock News
·
Yesterday

Junshi Biosciences Raises 700 Million Yuan Through Tech Innovation Bond Issuance

Stock News
·
Aug 21

Shareholder Offloads Nearly 7 Billion Yuan in Precision-Timed Selloff, Stake Drops to 3.79%

Deep News
·
Aug 21

JUNSHI BIO Sets 26 August 2026 Board Meeting to Review 1H 2026 Results

Bulletin Express
·
Aug 12

Junshi Biosciences Shareholder Cuts Stake

MT Newswires Live
·
Aug 11

JUNSHI BIO Shareholder He Ming Completes Sale of 882,600 Shares, Fulfilling Reduction Plan

Stock News
·
Aug 10

Junshi Biosciences Completes 300 Million Yuan Second Tranche Bond Issue

MT Newswires Live
·
Jul 23

Shanghai Junshi's Toripalimab Supplemental Application Accepted in China

MT Newswires Live
·
Jul 22

Shanghai Junshi Biosciences Gets NMPA Acceptance Notice of Supplemental Application for Toripalimab

Reuters
·
Jul 22

Shanghai Junshi Biosciences - Acceptance of Supplemental Application for Toripalimab in Combination with Chemotherapy as Perioperative Treatment

THOMSON REUTERS
·
Jul 21

Shanghai Junshi Biosciences - Acceptance Notice Issued by Nmpa China

THOMSON REUTERS
·
Jul 21

Zhongou Fund's Ge Lan Q2 Report Revealed: Junshi Bio Enters Top Holdings, Kelun Pharma Sees Major Increase

Deep News
·
Jul 21

HK Movers | Biomedical Stocks Rally; REMEGEN, WUXI XDC and KEYMED BIO-B Surge Over 8%

Tiger Newspress
·
Jul 20